A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover new drugs for cancer, neurology, and immunology.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Another innovation hub, in the southern city of Guangzhou, is planned for November. To date, six startups in China and other Asian countries have taken part in the German drugmaker's accelerator program.
Two drugs - Pfizer and Merck KGaA's Bavencio and AstraZeneca's Imfinzi - saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
Merck and Palantir Technologies are forming a joint research venture called Syntropy as a way to offer data analytics tools to healthcare organizations.
As part of the collaboration. Medisafe's digital health tool will be used for Merck KGaA's drugs spanning Type 2 diabetes, thyroid disorders, and cardiovascular diseases.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Blogging will be light today on MedCity News - most of the staff is off for the Columbus Day holiday.
It’s the sort of thing that was inevitable — two companies of the same name want a Facebook page. Administrative wires got crossed and hey, presto, we have a 21st century legal dispute to resolve. In this case, Merck KGAa, based in Darmstadt, Germany, filed a request for Facebook page www.facebook.com/merck in March 2010, according […]